礼邦医药董事长夏国尧为美国国籍，递表前夕套现1000万元

Core Viewpoint - Libang Pharmaceutical (Jiangsu) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on the renal disease biopharmaceutical sector with a comprehensive product portfolio [2][3]. Financial Performance - The company reported revenues of 0 RMB in 2023, 6.525 million RMB in 2024, and 12.112 million RMB in the first half of 2025, with losses of 365.256 million RMB, 335.130 million RMB, and 163.985 million RMB respectively during the same periods [3][4]. - The gross profit for 2024 is projected at 830 thousand RMB, while the gross profit for the first half of 2025 is expected to be 5.262 million RMB [4]. Product Pipeline - As of the latest feasible date, Libang Pharmaceutical has a product pipeline consisting of seven candidate products, three of which are in clinical stages, and one commercialized product, Meixinluo® [2]. Shareholder Structure - As of October 30, 2025, the largest single shareholder group holds approximately 24.50% of the issued share capital, with various entities holding specific percentages [3]. Recent Financing Activity - Prior to the listing application, Libang Pharmaceutical completed a cross-round financing on October 23, 2025, involving the transfer of shares among several entities for a total consideration of approximately 98.4175 million RMB [5][6]. Leadership Background - Dr. Gavin Guoyao Xia, the co-founder and CEO of Libang Pharmaceutical, has extensive experience in the healthcare sector, with over 15 years in drug development and management of biotech startups [10][11].